
Conference Coverage
Latest News

Board of Pharmacy Specialties Considers Specialty Certification for Veterinary Pharmacists

Bimagrumab–Semaglutide Combination Achieves Significant Weight Loss While Preserving Muscle Mass

What New Trial Data Reveal About Daratumumab Sensitivity in Newly Diagnosed Multiple Myeloma

Sibeprenlimab-szsi for Primary IgA Nephropathy: A New Drug Review

Expert Q&A: Separating Science From Hype in the Supplement Industry

Shorts










Podcasts
Videos
Continuing Education
All News

Patients receiving dialysis with primary care physicians had lower rates of emergency department visits compared with those without primary care involvement.

The approval is significant for a condition that is estimated to affect fewer than 1 in 1 million individuals.

A 4-day course of a mycelium-based supplement reduced reactogenicity and sustained antibody levels for up to 6 months in COVID-naive participants.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

It’s been building for quite a while, but the dam seems to be breaking, and the 2 themes seem to be transparency and fiduciary duty.

OTC naloxone nasal sprays expand overdose rescue; pharmacists guide proper use, tackle stigma, and help communities curb opioid deaths.

A large observational study identifies U-shaped relationship between weekday sleep duration and estimated glucose disposal rate.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Adherence to glucose-lowering drugs ranges from 41% to 68% depending on drug class.

Early detection and prevention reduce risks of diverse adverse drug reactions.

Look‑alike, soundalike drugs increase errors, but systems can prevent them.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Pharmacists quietly prevent medication harm, ease discharge chaos, and manage rising health care strain through unseen cognitive work.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

Peptide compounders face rising scrutiny as regulators and lawsuits lean on USP <795> and <797>.

As the spring travel season approaches, more than 30 countries appear on the CDC's circulating polio alert list.

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.

Pembrolizumab neoadjuvant immunotherapy hits approximately 70% complete responses in desmoplastic melanoma.

Phase 4 data show suzetrigine controls post–plastic surgery pain, keeping nearly 91% of patients opioid free with good pain ratings and tolerability.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.


























